BioXyTran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

To discover and develop life-saving and life-enhancing drugs through innovation and collaboration.

To be a leader in the development of therapeutic treatments to fight life-threatening diseases worldwide.

BioXyTran has been recognized for its achievements with numerous awards, including the prestigious Parexel Innovators Award and the IBM Watson Discoverers Award. The company has also received recognition in research and development from organizations such as the American Association for the Advancement of Science and the Association for Disease Modeling.